medigraphic.com

2022, Number 1

<< Back Next >>

Folia 2022; 16 (1)

Stevens Johnson Syndrome

Daza VJT, Gutiérrez AEY, O´Farril HV

Language: Spanish
References: 11
Page:
PDF size: 282.59 Kb.


ABSTRACT

Stevens Johnson syndrome is a severe, often fatal acute dermatosis, characterized by general malaise, stomatitis, purulent conjunctivitis, and vesiculobullous lesions disseminated over the entire body surface. It is triggered by viral or bacterial infections and, basically, by medications. The case of a 23-year-old female patient is reported. She had a personal pathological history of epilepsy, for which she had been treated with carbamazepine for more or less 21 days. She was admitted to Miguel Enríquez Clinical Surgical Hospital in Havana with a suspected dengue diagnosis due to fever and rash, with worsening of the dermatological symptoms, so she was evaluated in the Dermatology consultation. Given the possibility of being in the presence of Stevens Johnson syndrome, she was indicated to stop medication and to add oral steroids to the treatment, which improved her clinical condition. Hence, the objective of this article was to describe the case due to the importance of always taking this entity into account, in order to make an early diagnosis and timely treatment.


REFERENCES

  1. Bolognia JL, Schaffer J, Cerroni L. Dermatología. 4 ed. Barcelona: Elsevier; 2018.

  2. Arenas R. Dermatología atlas diagnóstico y tratamiento. 6 ed. México: Mc Graw-Hill; 2015. p. 27-36.

  3. James W, Berger T, Dirk E. Andrews' Diseases of the Skin. 13th ed. New York: Elsevier; 2019.

  4. Halevy S, Ghislain PD, Mockenhaupt M. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol. 2008;58(1):25-32. DOI: https://dx.doi.org/10.1016/j.jaad.2007.08.036

  5. Hung SI, Chung WH, Liou LB. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA. 2005;102(11):4134-9. DOI: https://dx.doi.org/10.1073/pnas.0409500102

  6. Katz S, Gilchrest B, Paller A, Leffell D, Wolff K. Fitzpatrick Dermatología en Medicina General. Tomo II. 8 ed. Buenos Aires: Editorial Panamericana; 2016. p. 963.

  7. Atuesta JJ, Chalela JG, Pérez M, Rodríguez G. Urgencias en dermatología. Bogota: Schering Plough; 1999. p. 53-60.

  8. Sassolas B, Haddad C, Mockenhaupt M, Dunant A. ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis: comparison with case control analysis. Clin Pharmacol Ther. 2010;88(1):60-8. DOI: https://dx.doi.org/10.1038/clpt.2009.252

  9. Ghislain PD, Roujeau JC. Treatment of severe drug reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome. Dermatol Online J. 2002;8(1):5. PMID: 12165215

  10. Araki Y, Sotozono C, Inatomi T, Ueta M, Yokoi N, Ueda E, et al. Successful treatment of Stevens-Johnson syndrome with steroid pulse therapy at disease onset. Am J Ophthalmol. 2009;147(6):1004-11. DOI: https://dx.doi.org/10.1016/j.ajo.2008.12.040

  11. Kardaun SH, Jonkman MF. Dexamethasone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis. Acta Derm Venereol. 2007;87(2):144-8. DOI: https://dx.doi.org/10.2340/00015555-0214




2020     |     www.medigraphic.com